With deadlines looming to file plans for next year’s Affordable Care Act marketplaces, health insurers are struggling to respond to mixed signals from the Trump administration, delaying key business decisions and scouring Twitter for hints from Washington about the law’s future.

Buoyed by Congress’ failed attempt last week to replace the Affordable Care Act, California officials, health advocates and insurance executives are pressing forward on a new phase of resistance against GOP efforts to weaken the health care law.

The pharmaceutical industry for years has fended off calls for government to controls prices despite the growing uproar over soaring prescription drug costs.,

Joel Hay, a professor at the University of Southern California, describes his political views as “conservative, free market.” But in a counterintuitive twist, his proposal to fix the Affordable Care Act would expand the largest source of public health coverage in the country: Medicaid.

Some California state senators are spending their spring break up north, on a weeklong trip to Canada to study its single-payer healthcare system.

In November, California voters defeated a ballot proposal that would have given state government more control over drug prices. It was a victory for pharmaceutical companies, which spent more than $100 million campaigning against the measure.